e8va12b
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-A
FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES
PURSUANT TO SECTION 12(b) OR (g) OF THE
SECURITIES EXCHANGE ACT OF 1934
HALOZYME THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
Nevada
(State of incorporation)
|
|
88-0488686
(I.R.S. Employer Identification No.) |
|
|
|
11588 Sorrento Valley Road, Suite 17 |
|
|
San Diego, California
|
|
92121 |
(Address of principal executive offices)
|
|
(Zip Code) |
Securities to be registered pursuant to Section 12(b) of the Act:
|
|
|
Title of each class
|
|
Name of each exchange on which |
to be so registered
|
|
each class is to be registered |
|
|
|
Common Stock, $0.001 Par Value
|
|
The Nasdaq Stock Market LLC |
If this Form relates to the registration of a class of securities pursuant to Section 12(b) of the
Exchange Act and is effective pursuant to General Instruction A.(c),
check the following box. þ
If this Form relates to the registration of a class of securities pursuant to Section 12(g) of
the Exchange Act and is effective pursuant to General Instruction A.(d), check the following box.
o
Securities Act registration statement file number to which this form relates:
Not applicable
Securities to be registered pursuant to Section 12(g) of the Act:
None
Item 1. Description of Registrants Securities to be Registered
The capital stock of Halozyme Therapeutics, Inc. (the Company) to be registered on The
Nasdaq Stock Market LLC is the Companys Common Stock with a par value of $0.001 per share.
The description of the Companys Common Stock contained in the Companys prospectus dated
December 14, 2005, as a part of the Registration Statement on Form S-3, File No. 333-125731, is
incorporated by reference, subject to the rights described in the
following sentence and provided that 150,000,000 shares of Common Stock
are now authorized and 71,913,411 shares of Common Stock were
outstanding as of April 30, 2007. In addition, the description
of the rights held by each share of Company Common Stock pursuant to
the Companys Stockholder Rights Plan, as set forth in the
Companys Form 8-K filed on May 8, 2006, is also
incorporated by reference.
Item 2. Exhibits
Not applicable.
SIGNATURE
Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the
Registrant has duly caused this registration statement to be signed on its behalf by the
undersigned, thereto duly authorized.
Date: May 9, 2007
|
|
|
|
|
|
Halozyme Therapeutics, Inc.
|
|
|
By: |
/s/ David Ramsay
|
|
|
|
David Ramsay |
|
|
|
Secretary and Chief Financial Officer |
|
|